FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject	STATEMENT
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed nu

FOF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol IVERIC bio, Inc. [ISEE]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
SBLENDORIO GLENN						TYDICE OID, IIIC. [ISEE]								X	X Director		10% Owner		vner	
(Last)	(F	rst) (ľ	Middle)		3. Da	Date of Earliest Transaction (Month/Day/Year)								X	Office belov	er (give title v)		Other (s	specify	
C/O IVERIC BIO, INC.						11/02/2022								CEO						
8 SYLVA																				
	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable										
(Street)														Line) X	Form	n filed by One Departing Deven			nn	
PARSIPI	PANY N	J 0	7054											Λ	Form filed by One Reporting Person Form filed by More than One Reporting					
															Perso		io tilali oi	СПОР	Jruing	
(City)	(S	tate) (Z	Zip)																	
		Table	I - No	on-Deriva	tive S	Secui	rities	Acc	uired	d, Dis	posed of	, or E	Benefic	cially	Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)					4 and 5) Secu Bene Own		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) o (D)	Price			ted action(s) 3 and 4)			(Instr. 4)	
Common Stock 11/02				11/02/2	.022				S ⁽¹⁾		50,000	D	\$23.	01(2))1 ⁽²⁾ 179,689		D			
		Tal	ole II	- Derivati	ive Se	curit	ies A	Acqu	ired,	Disp	osed of,	or Be	nefici	ally (Owne	 d				
											convertib									
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8)		of	ired r osed) : 3, 4		ation D			int of rities rlying ative rity (Instr	Der Sec (Ins	rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4		Beneficial Ownership t (Instr. 4)			
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares							

Explanation of Responses:

Remarks:

/s/ Todd D.C. Anderman, as Attorney-in-Fact for Glenn P.

11/04/2022

Sblendorio

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. The sales reported on this Form 4 are the final shares to be sold under the above referenced Rule 10b5-1 trading plan. This plan is now terminated.

^{2.} The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from \$22.54 to \$23.65 per share on November 2, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.